Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01775800 · ClinicalTrials.gov registry record · NA

Treatment Modification to Reduce Symptom Burden in Hemodialysis

A NA study of End Stage Renal Disease, sponsored by The Rogosin Institute.

Completed
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT01775800: Completed NA study of End Stage Renal Disease, sponsored by The Rogosin Institute.

NCT01775800 is a NA study of End Stage Renal Disease that has completed, run by The Rogosin Institute. The registered enrollment target is 16 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01775800, a NA study of End Stage Renal Disease, has completed, sponsored by The Rogosin Institute.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects. Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.

Conditions Studied

Interventions

  • OTHER Treatment modification

Study Locations (1)

New York

  • The Rogosin Institute - New York

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2013-01
Est. Completion 2014-09
Phase NA
The Rogosin Institute

21 total trials

What the finished NCT01775800 record still lists

NCT01775800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower).

The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Treatment modification is the first listed.

NCT01775800 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01775800 about?

NCT01775800 is a clinical study titled "Treatment Modification to Reduce Symptom Burden in Hemodialysis". Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosph...

What is the current status of trial NCT01775800?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2013-01. Estimated completion is 2014-09.

What conditions does trial NCT01775800 study?

This clinical trial studies the following conditions: End Stage Renal Disease.

What interventions are being tested in trial NCT01775800?

The interventions under investigation include: Treatment modification (OTHER).

Who is sponsoring clinical trial NCT01775800?

This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01775800 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01775800's enrollment target sits among peer trials

16 72nd of 86 higher than 14 of 86 other End Stage Renal Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01775800, the US trial registry maintained by the National Library of Medicine. NCT01775800 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.